Roche taps Simcere for trispecific T cell engager pact with $75M upfront
For the second time in as many weeks, Roche's business development team has lined up a deal with a Chinese biopharma. The Swiss drug giant this time is teaming with Simcere Zaiming on a preclinical ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.